Physician profile
Ron Yamane
NPI 1649383308
$4,598.69
in general payments reported to CMS, 2019-2025
22 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $401 · 2021: $739 · 2022: $904 · 2023: $717 · 2024: $199 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $913.68 | 2019-2024 | Xarelto |
| Amgen INC. | $653.06 | 2019-2024 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals Lp | $637.78 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $536.89 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $256.08 | 2022-2024 | Mounjaro, Zepbound, Emgality |
| Amarin Pharma, INC. | $213.14 | 2020-2021 | |
| Esperion Therapeutics, INC. | $184.33 | 2020-2021 | |
| Glaxosmithkline, LLC. | $183.42 | 2019-2023 | Arexvy |
| Radius Health, INC. | $179.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.08 | 2019-2022 | |
| Pfizer INC. | $126.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $117.88 | 2022 | |
| Almatica Pharma LLC | $100.22 | 2021-2023 | Loreev Xr |
| Alexion Pharmaceuticals, INC. | $68.35 | 2021 | |
| Horizon Therapeutics Plc | $67.30 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $41.42 | 2020 | |
| Hikma Pharmaceuticals USA | $40.55 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $40.24 | 2019 | |
| Merck Sharp & Dohme LLC | $31.23 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.63 | 2022 | |
| Biogen, INC. | $20.36 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.91 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Yamane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.